Profile

Dr. 安部 秀斉

所属病院
徳島大学大学院
医歯薬学研究部 腎臓内科学分野
Locations
徳島県徳島市蔵本町3-18-15
Phone
088-633-7184
Dr. 安部 秀斉に治療相談のお申し込み
  • About me私について

    京都大学医学部卒、徳島大学腎臓内科准教授です。京都大学時代は、がん免疫薬「オプジーボ」で知られる
    抗PD-1癌免疫療法に関して、2018年のノーベル生理学・医学賞を受賞された本庶佑教授の元で、基礎研究の薫陶を受け、
    その後、腎臓病・透析療法の診療を20年余り継続している専門医です。
    近年は、さまざまな新たな抗ガン剤による腎障害の患者さんが増え、onconephrology(腫瘍腎臓学)という新分野で
    患者さんの腎機能を守る診療を行っています。また、腎機能低下がもともとある場合も、利用できる薬剤の種類や量が
    変ってきますので、ベストの治療法をご提案させていただきます。

  • Career経歴

    1993年3月 京都大学医学部医学科卒業
    2001年3月 京都大学医学部大学院医学研究科博士課程修了 学位(医学博士):博第2380号
    2001年3月 京都大学医学部附属病院 老年科 研修医、静岡県立総合病院 循環器科 医員
    2001年3月 徳島大学病院 検査部 医員、徳島大学病院 腎臓内科
    2004年9月 生産開発科学研究所 主任研究員 (兼 徳島大学 病態情報診断学 非常勤講師)
    2008年4月 徳島大学病院 検査部 講師
    2009年7月 徳島大学大学院 ヘルスバイオサイエンス研究部 病態情報医学講座 腎臓内科学分野 准教授
    2015年4月 徳島大学大学院 医歯薬学研究部 腎臓内科学分野 准教授
    2019年10月 徳島大学産業院 准教授
  • Affiliation所属学会

    本内科学会(専門医、指導医、支部評議員)

    日本腎臓学会(専門医)

    米国内科学会

    国際腎臓学会

    米国腎臓学会

    日本透析医学会(専門医)

    日本糖尿病学会

    日本老年医学会(代議員)

    日本臨床検査医学会

    人工知能学会

    日本生化学会

    日本分子生物学会

  • Specialized field / Recommendation専門分野 / 推薦

    □腎臓病治療全般

    □透析医療全般

    □onconephrology(腫瘍腎臓医療)

    □がん種 全般

  • Qualification · Awards history資格・受賞歴

    日本腎臓学会(専門医)

    日本透析医学会(専門医)

    日本老年医学会(代議員)

    日本内科学会(専門医、指導医、支部評議員)

    2003年 第8回 シンポジウム糖尿病 最優秀賞

    2005年 第13回 日本血管生物医学会 優秀賞​

    2007年 第15回 日本血管生物医学会 優秀賞​

    2008年 第12回 シンポジウム糖尿病 最優秀賞​

    2010年 第47回 日本臨床分子医学会学術集会 学術奨励賞​

    2010年 第2回 腎疾患と高血圧研究会 研究賞

    2012年 近藤記念医学財団 学術奨励賞​

  • Medical society papers ・ Presentation history論文・発表歴

    • Nishimura K, Abe H, et al.

      Circulating Apolipoprotein L1 is associated with insulin resistance-induced abnormal lipid metabolism.

    • Abe H*, Doi T.

      New Insight into Molecular Function of Smads Signalings in Diabetic Nephropathy.

    • Sakurai A, Abe H*, et al.

      Involvement of Elf3 on Smad3 activation-dependent injuries in podocytes and excretion of urinary exosome in diabetic nephropathy.

    • Shibata E, Abe H, et al.

      The utility and limitation of inferior vena cava diameter as a dry weight marker.

    • Obata F, Abe H*, et al.

      Direct oral anticoagulant successfully used to treat an adult nephrotic patient complicated with portal vein thrombosis.

    • Abe H*, Sakurai A, Ochi A.

      Induction of steady-state glomeruloid sphere by self-assembly from human embryonic kidney cells.

    • Tamaki M, Abe H, et al.

      All-trans retinoic acid suppresses bone morphogenetic protein 4 in mouse diabetic nephropathy through a unique retinoic acid response element.

    • Abe H*, Tominaga T.

      New insights into the molecular pathology and the development of predictive biomarkers in diabetic mephropathy. (review) Abe H*, Tominaga T.

    • Ueda S, Abe H, et al.

      Systemic Sarcoidosis Presenting with Renal Involvement Caused by Various Sarcoidosis-associated Pathophysiological Conditions.

    • Abe H*, Sakurai A, et al.

      Urinary Exosomal mRNA of WT1 as Diagnostic and Prognostic Biomarker for Diabetic Nephropathy.

    • Fujita Y, Tominaga T, Abe H, et al.

      An adjustment in BMP4 function represents a treatment for diabetic nephropathy and podocyte injury.

    • Kishi S, Abe H, et al.

      Lambda Light Chain Non-crystalline Proximal Tubulopathy with IgD Lambda Myeloma.

    • Ono H, Abe H*, et al.

      Novel Interplay Between Smad1 and Smad3 Phosphorylation via AGE Regulates the Progression of Diabetic Nephropathy.

    • Nagai K, Abe H, et al.

      Progressive renal insufficiency related to ALK inhibitor, alectinib.

    • Kishi F, Abe H, et al.

      Urinary type IV collagen excretion is involved in the decline in estimated glomerular filtration rate in the Japanese general population without diabetes: A 5-year observational study.

    • Shimizu M, Abe H, et al.

      Urinary IgG4 and Smad1 are Specific Biomarkers for Renal Structural and Functional Changes in Early Stage of Diabetic Nephropathy.

    • Shimizu M, Abe H, et al.

      Decline in estimated glomerular filtration rate is associated with risk of end-stage renal disease in type 2 diabetes with macroalbuminuria: an observational study from JDNCS.

    • Nagai K, Abe H, et al.

      Mesangial Cell Mammalian Target of Rapamycin Complex 1 Activation Results in Mesangial Expansion.

    • Kishi S, Abe H, et al.

      IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma.

    • Ono H, Abe H, et al.

      Shunt Nephritis and Pyogenic Spondylitis With a Positive PR3-ANCA Associated With Chronically Infected Ventriculoatrial Shunt.

    • Obata F, Murakami T, Abe H, et al.

      A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant.

    • Ono H, Nagai K, Abe H, et al.

      Re-recognition of Age-dependent Reference Range for the Serum Creatinine Level in Teenagers - A Case of Slowly Progressive Tubulointerstitial Nephritis which Occurred in an Adolescent.

    • Ono H, Murakami T, Abe H, et al.

      Successful treatment of highly advanced immunoglobulin G4-related kidney disease presenting renal mass-like regions with end-stage kidney failure: a case study.

    • Yoshimoto S, Abe H, et al.

      Influential factors on serum albumin concentration in hospitalized chronic kidney disease patients.

    • Arai H, Abe H*, et al.

      Probucol modulates Nrf2 function and ameliorates diabetic nephropathy in db/db mice.

    • Matsuura M, Abe H, et al.

      A Novel Method of DAPI Staining for Differential Diagnosis of Renal Amyloidosis.

    • Araki M, Matsubara T, Abe H*, et al.

      Conditional Deletion of Smad1 Ameliorates Glomerular Injury in Progressive Glomerulonephritis.

    • Hirano T, Murakami T, Abe H, et al.

      A Novel Interaction between FLICE-Associated Huge Protein (FLASH) and E2A Regulates Cell Proliferation and Cellular Senescence via Tumor Necrosis Factor (TNF)-Alpha-p21WAF1/CIP1 Axis.

    • Matsubara T, Araki M, Abe H*, et al.

      Bone Morphogenetic Protein 4 and Smad1 Mediate Extracellular Matrix Production in the Development of Diabetic Nephropathy.

    • Nagai K, Miyoshi M, Abe H, et al.

      Dual involvement of growth arrest-specific gene 6 in the early phase of human IgA nephropathy.

    • Yoshikawa K, Abe H, et al.

      Polymorphism in the human matrix Gla protein gene is associated with the progression of vascular calcification in maintenance hemodialysis patients.

    • Furuichi K, Shimizu M, Abe H, et al.

      Japan Diabetic Nephropathy Cohort Study: study design, methods, and implementation.

    • Kishi S, Yamada S, Abe H, et al.

      Acute Glomerulonephritis in an Immunocompetent Elderly Woman after Contact with a Child who Had Been Diagnosed as Erythema Infectiosum.

    • Torikoshi K, Abe H, et al.

      Protein Inhibitor of Activated STAT, PIASy Regulates α-Smooth Muscle Actin Expression by Interacting with E12 in Mesangial Cells.

    • Abe H, Tominaga T, et al.

      Scleraxis modulates bone morphogenetic protein 4 (BMP4)-Smad1-smooth muscle α actin (SMA) signal transduction in diabetic nephropathy.

    • Kishi S, Abe H, et al.

      Sox9 induces a chondrogenic phenotype of mesangial cells and contributes to advanced diabetic nephropathy.

    • Abe H.

      Recent progress in understanding the molecular pathogenesis of diabetic nephropathy.

    • Mima A, Shiota F, Abe H, et al.

      An autopsy case of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) with intestinal bleeding in chronic renal failure.

    • Murakami T, Nagai K, Abe H, et al.

      MPO-ANCA-positive anti-glomerular basement membrane antibody disease successfully treated by plasma exchange and immunosuppressive therapy.

    • Tominaga T, Abe H, et al.

      Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy.

    • Mima A, Abe H, et al.

      Activation of Src Mediates PDGF-Induced Smad1 Phosphorylation and Contributes to the Progression of Glomerulosclerosis in Glomerulonephritis.

    • Abe H, Matsubara T, Arai H, Doi T.

      Role of Smad1 in diabetic nephropathy: Molecular mechanisms and implications as a diagnostic marker.

    • Murakami T, Abe H, et al.

      Trophoblast glycoprotein: possible candidate mediating podocyte injuries in glomerulonephritis.

    • Araoka T, Abe H, et al.

      Transcription factor 7-like 2 (TCF7L2) regulates activin receptor-like kinase 1 (ALK1)/Smad1 pathway for development of diabetic nephropathy.

    • Araoka T, Takeoka H, Abe H, et al.

      Early Diagnosis and Treatment may Prevent the Development of Complications in an Adult Patient with Glycogen Storage Disease Type Ia.

    • Araoka T, Abe H, et al.

      Successful management of refractory pleural effusion due to systemic immunoglobulin light chain amyloidosis by vincristine adriamycin dexamethasone chemotherapy: a case report.

    • Mima A, Abe H, et al.

      Successful treatment of membranoproliferative glomerulonephritis associated with hepatitis B and C virus simultaneous infection patient.

    • Takamatsu N, Abe H, et al.

      Risk factors for chronic kidney disease in Japan: a community-based study.

    • Mima A, Abe H, et al.

      Angio-embolization of renal artery pseudoaneurysm after renal biopsy: a case report.

    • Doi T, Abe H, et al.

      The current clinical problems for early phase of diabetic nephropathy and approach for pathogenesis of diabetic nephropathy.

    • Mima A, Arai H, et al.

      Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy.

    • Kanamori H, Abe H, et al.

      Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy.

    • Nakao K, Abe H, et al.

      Evaluation of atrial and brain natriuretic polypeptides in association with angiotensin-converting enzyme gene polymorphism in Japanese non-diabetic hemodialysis patients.

    • Mima A, Abe H, et al.

      Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy.

    • Matsubara T, Abe H, et al.

      Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy.

    • Takahashi T, Abe H, et al.

      Activation of STAT3/Smad1 is a key signaling pathway for progression to glomerulosclerosis in experimental glomerulonephritis.

    • Ohashi S, Abe H, et al.

      Advanced glycation end products increase collagen-specific chaperone protein in mouse diabetic nephropathy.

    • Abe H, et al.

      Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation.

    • Makibayashi K, Abe H, et al.

      A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis.

    • Abe H, et al.

      A vitamin D analog regulates mesangial cell smooth muscle phenotypes in a transforming growth factor-beta type II receptor-mediated manner.

    • Takeoka H, Abe H, et al.

      A multifunctional transcription factor (A1p145) regulates the smooth muscle phenotype in mesangial cells.

Dr. 安部 秀斉に治療相談のお申し込み

Dr. 安部 秀斉 の関連サイト